The new NICE treatment guidelines for Osteoarthritis with Mr Christopher Martey - Part 1

<p>This is the first episode in our podcast mini-series about the new NICE guidelines for Osteoarthritis.   Mel Brooke, the Patient and Public Engagement Programme Director (BIRD) talks with expert guest Mr Christopher Martey, chartered physiotherapist who explains the NICE guidelines background and updates that were published in 2022.  </p> <p>If you can please rate our podcasts on your listening platform.  Did you know you can also access all our information podcasts direct from BIRDs website?  Simply visit <a href="https://www.birdbath.org.uk/podcasts">www.birdbath.org.uk/podcasts</a> and scroll down the page to find the one you are looking for.</p> <p>Useful links:</p> <p><a href="http://arma.uk.net" target="_blank" rel="noopener noreferer">The Arthritis and Musculoskeletal Alliance (ARMA)</a></p> <p><a href="https://www.england.nhs.uk/personalisedcare/shared-decision-making/decision-support-tools/" target="_blank" rel="noopener noreferer">NHS England Decision Support Tools</a></p> <p><a href="https://www.nice.org.uk/guidance/ng226" target="_blank" rel="noopener noreferer">NICE Guidance for OA</a></p> <p><a href="https://www.versusarthritis.org/about-arthritis/healthcare-professionals/musculoskeletal-decision-support-tools/" target="_blank" rel="noopener noreferer">Versus Arthritis</a></p> <p>Please note: All content for BIRD&#39;s PPE podcasts are created for information purposes only and not intended to be a substitute for individual medical advice, diagnosis, or treatment. Always seek the advice of your physician or health provider with any questions you may have about your medical condition. Reliance on any information provided by BIRD or any of the expert podcast guests is solely at your own risk.</p> <p>The Patient and Public Engagement Programme is supported by hands-off sponsorships from Eli Lilly and Company Limited, UCB and Amgen - all of whom have provided grant funding but who have had no involvement in the development, content or editorial control of this podcast, nor the subsequent review and ap